AVANIR Pharmaceuticals Invites Investors to Listen to the Lazard Capital Markets 3rd Annual Life Sciences Conference Webcast

San Diego, Calif., November 15, 2006 -- Avanir Pharmaceuticals (NASDAQ: AVNR) will be presenting at Lazard Capital Markets 3rd Annual Life Sciences Conference on Tuesday, November 28, 2006 at 8:30 a.m. ET in New York, New York.  Avanir's Senior Vice President of Sales and Marketing, Keith Katkin, will be presenting at the investor conference.

 

The presentation will be available via a live webcast accessible through Avanir's corporate website at www.avanir.com.  To access the webcast, log on to Avanir's site fifteen minutes prior to the presentation to register and download any necessary audio software.  An archive of the presentation will be available for 90 days following the event. 

 

About Avanir

Avanir Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.  Avanir's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases.  Avanir currently markets FazaClo®, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments.  FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder.  For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com.  Zenvia™, Avanir's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA and future development plans for this product candidate are under consideration.  The Company does not know at this time what impact, if any, the ongoing discussions with the FDA for IEED may have on the development of Zenvia for other indications.  Additionally, Avanir has completed the patient recruitment in a Phase III clinical trial with Zenvia as a potential treatment for patients with painful diabetic neuropathy.  Avanir has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease.  The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.  Further information about Avanir can be found at www.avanir.com.

 

Avanir Pharmaceuticals Contacts:

Patrick O'Brien                                                    

949-389-6789                                                   

pobrien@avanir.com                                          

 

Nov 15, 2006